Curetis to host Conference Call and Webcast on EIB Debt

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Curetis to host Conference Call and Webcast on EIB Debt Financing Facility and Gyronimo Asset Acquisition

Curetis to host Conference Call and Webcast on EIB Debt Financing Facility and Gyronimo Asset Acquisition

Amsterdam, the Netherlands and Holzgerlingen, Germany, December 13, 2016 -- Curetis N.V. (the " Company " and, together with Curetis GmbH, " Curetis "), a developer of next-level molecular diagnostic solutions, today announced that it will host a public conference call and webcast on December 13, 2016, at 03:00 pm CET / 09:00 am EST to present details on the debt financing facility agreement with the European Investment Bank (EIB) and its asset acquisition agreement with Carpegen GmbH and Systec GmbH announced earlier today.

The conference call will be supplemented by a presentation, which can be accessed during the call at http://www.curetis.com/en/investors/backgroun...ation.html . The live webcast and a replay will be available at http://curetis131216-live.audio-webcast.com through the participants' passcode curetis1216

To access the call, please dial one of the following numbers using the passcode 93120684#

Germany: +49 692 222 290 43

UK: +44 203 009 2452

US: +1 855 402 7766

For further international dial-in numbers, please open the following link: http://events.arkadin.com/ev/docs/International Access Numbers_ UKFELBRI1_SU7.pdf

Disclaimer CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.

###

About Curetis Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.

For further information, please visit www.curetis.com .

Legal Disclaimer This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contact details

Curetis Max-Eyth-Str. 42 71088 Holzgerlingen, Germany Tel. +49 7031 49195-10 pr@curetis.com or ir@curetis.com www.curetis.com - www.unyvero.com

International Media & Investor Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners info(@)akampion.com Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68

U.S. Media & Investor Inquiries The Ruth Group Lee Roth lroth@theruthgroup.com Tel. +1 646 536 7012

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...d8773a6626

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attachm...de7d66156f

Scroll down for more posts ▼

Top 10 Most Recent News Articles

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 543

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 117

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 8

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 0

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 71

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 349

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading

Top 5 Most Recently Viewed Articles

Inventiva's Significant Capital Boost Through Public Offering

Updated Category News Views 276

Inventiva's Upsized Public Offering Explained Inventiva, a clinical-stage biopharmaceutical company known for its focus on developing oral therapies targeting metabolic disorders, has recently announced the pricing details of its public offering. This significant initiative is set to raise around $150 million by selling approximately 38.96 million American Depositary...

Continue Reading
The Future of AI: How Innovations Drive Market Growth

Updated Category News Views 264

AI Market Growth Overview The artificial intelligence (AI) market is set for substantial growth, projected to increase by USD 237.4 billion from 2024 to 2028. The forecast indicates a remarkable compound annual growth rate (CAGR) of 30.07% during this period. This growth can largely be attributed to the rising demand for effective solutions in fraud prevention and the...

Continue Reading
commercetools Compilations: Innovations Driving Digital Growth

Updated Category News Views 177

Exciting Launch of commercetools Compilations commercetools has unveiled Compilations, a semi-annual showcase that highlights more than 50 product enhancements, demonstrating the organization’s dedication to innovation and improved customer experiences for users of the commercetools Platform. With over 13,000 deployments and 200 releases, this initiative significantly...

Continue Reading
AKOOL's Agentic Canvas: AI Execution Revolution

Updated Category News Views 23

AKOOL Elevates AI from Chat to Execution Well, folks, it looks like AKOOL is shaking things up in the world of artificial intelligence. Forget about AI that's just about chatting away and searching for answers like a digital gopher. This time, AKOOL is bringing something new to the table with its Agentic Canvas, and it's a real game-changer for anyone still fooling around...

Continue Reading
Qudian Inc. Transitions to High Templar Tech Limited

Updated Category News Views 222

Qudian Inc. Transitions to High Templar Tech Limited Qudian Inc., a technology-driven consumer company in China, has officially announced its rebranding to High Templar Tech Limited along with a change in its stock ticker from "QD" to "HTT". This significant decision reflects the company's evolving strategy and commitment to enhancing consumer experiences through...

Continue Reading